获得性活化蛋白C抵抗发生机制

顾佳鑫; 高玉娟; 刘述川; 苏雁华

doi:10.13201/j.issn.1004-2806.2019.05.018

获得性活化蛋白C抵抗发生机制

- 哈尔滨医科大学第一附属医院(哈尔滨, 150000)

详细信息

通讯作者: 苏雁华,E-mail:suyanhua163@163.com

中图分类号: R554

收稿日期: 2018-07-19

Mechanisms of acquired activated protein C resistance

More Information

Corresponding author: SU Yanhua, E-mail: suyanhua163@163.com

Received Date: 19 July 2018

摘要

- 活化蛋白C抵抗 /
- Leiden FⅤ突变 /
- 炎症因子 /
- 蛋白S /
- 抗磷脂抗体
Abstract: Protein C system is an important anticoagulant system that plays a significant role in balancing the coagulation and fibrinolysis.Proteolytic inactivation of FⅤa and FⅧa by activated protein C (APC) is activated by thrombin bound to thrombomodulin,and its cofactors protein S and FⅤ is a key process in the physiological down-regulation of coagulation.Functional abnormality of this pathway is called APC resistance,which is associated with an increased risk of venous thrombosis.APC resistance was discovered in thrombophilic families originally and later showed to be associated with the Leiden FⅤ mutation.Leiden FⅤ is the major cause of hereditary APC resistance,while acquired conditions contribute to APC resistance and increase the risk of venous thrombosis.This paper reviews the mechanisms of acquired APC resistance.
- activated protein C resistance /
- Leiden FⅤ mutation /
- inflammatory factor /
- protein S /
- antiphospholipid antibody

HTML全文

参考文献(16)

[1]	Esmon CT.Protein C anticoagulant system-anti-inflammatory effects[J].Semin Immunopathol, 2012, 34:127-132.
[2]	Xie W, Liu Z, Chen B.Protein C deficiency resulting from two mutations in PROC presenting with recurrent venous thromboembolism[J].J Vasc Surg Cases Innov Tech, 2017, 3:254-256.
[3]	胡豫.中国人群静脉血栓形成的分子遗传学研究[J].临床血液学杂志, 2013, 26(1):4-8.
[4]	Chen C, Yang L, Villoutreix BO, et al.Gly74Ser mutation in protein C causes thrombosis due to a defect in protein S-dependent anticoagulant function[J].Thromb Haemost, 2017, 117:1358-1369.
[5]	Marlar RA, Gausman JN.Assessment of hereditary thrombophilia:performance of protein C (PC) testing[J].Methods Mol Biol, 2017, 1646:145-151.
[6]	Marlar RA, Gausman JN.Assessment of hereditary thrombophilia:performance of protein S (PS) testing[J].Methods Mol Biol, 2017, 1646:153-160.
[7]	Pilli VS, Plautz W, Majumder R.The journey of protein s from an anticoagulant to a signaling molecule[J].JSM Biochem Mol Biol, 2016, 3:1014.
[8]	Fernández JA, Xu X, Sinha RK, et al.Activated protein C light chain provides an extended binding surface for its anticoagulant cofactor, protein S[J].Blood Adv, 2017, 1:1423-1426.
[9]	Amiral J, Vissac AM, Seghatchian J.Laboratory assessment of activated protein C resistance/factor V-Leiden and performance characteristics of a new quantitative assay[J].Transfus Apher Sci, 2017, 56:906-913.
[10]	Bouwens EA, Stavenuiter F, Mosnier LO.Cell painting with an engineered EPCR to augment the protein C system[J].Thromb Haemost, 2015, 114:1144-1155.
[11]	Misasi R, Capozzi A, Longo A, et al."New" antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndrome[J].J Immunol Res, 2015, 2015:858542.
[12]	Hayashi T, Suzuki K.Changes of expression of the protein C pathway components in LPS-inducedendotoxemia——implication for sepsis[J].Cardiovasc Hematol Disord Drug Targets, 2015, 15:2-9.
[13]	Harrington LB, Marck BT, Wiggins KL, et al.Cross-sectional association of endogenous steroid hormone, sex hormone-binding globulin, and precursor steroid levels with hemostatic factor levels in postmenopausal women[J].J Thromb Haemost, 2017, 15:80-90.
[14]	Martos L, Ramón LA, Oto J, et al.α2-macroglobulin is a significant in vivo inhibitor of activated protein C and low APC:α2M levels are associated with venous thromboembolism[J].Thromb Haemost, 2018, 118:630-638.
[15]	Maroney SA, Mast AE.New insights into the biology of tissue factor pathway inhibitor[J].J Thromb Haemost, 2015, 13:S200-S207.
[16]	La Mura V, Tripodi A, Tosetti G, et al.Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis[J].Liver Int, 2016, 36:1322-1330.